Clinical trial NCT01954017: STP206 for the Prevention of Necrotizing Enterocolitis (NEC)
Official title: A Phase Ib Randomized, Placebo Controlled Study of the Safety and Efficacy of Once Daily Dosing of STP206 in Premature Very Low Birth Weight and Extremely Low Birth Weight Neonates
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Necrotizing Enterocolitis
Lead sponsor: Leadiant Biosciences, Inc.
Sponsor class: INDUSTRY
First posted: 2013-10-01
Enrollment: 103
Sex: ALL
Minimum age (years): 1
Maximum age (years): 4
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study is a sequential dose escalation study to assess the safety, tolerability, and preliminary NEC-preventative efficacy of two doses of STP206 versus control in very low birth weight and extremely low birth weight neonates.

Detailed description: Protocol STP206-002 is designed as a multi-center, randomized, double-blind, placebo controlled dose escalation study of the safety and tolerability of two doses of STP206 versus control in four sequentially decreasing birth weight strata. The primary objective of this study is to assess the safety and tolerability of once daily dosing of two dose levels of STP206 versus control in four different birth weight strata in premature neonates. Secondary objectives of this study include assessment of fecal shedding of STP206 throughout dosing and describing the incidence of NEC, incidence of relevant clinical events (sepsis/bacteremia, feeding intolerance, morbidity/complications of prematurity) and neonatal growth progression in the STP206 and control treatment groups.

Neonates for whom informed consent is obtained and who meet eligibility criteria will be eligible to enroll in this study. All neonates enrolled will receive daily doses of blinded study treatment for between 2 and 11 weeks with the duration of dosing based upon gestational age at birth. All neonates enrolled in the study will be placed under Universal Precautions and all study personnel with subject contact are trained in appropriate neonatal intensive care unit (NICU) infection control practices. While in the NICU, neonates will be evaluated daily for signs/symptoms of NEC, feeding volumes/feeding tolerance, adverse events, and concomitant medications. Physical examinations and vital signs will be performed daily during the dosing period and at the end of dosing/NICU discharge. Growth assessments will be performed every other week while in the NICU and at the end of dosing/NICU discharge. Assessments for complications of prematurity, including retinopathy of prematurity (ROP), intraventricular hemorrhage (IVH), and bronchopulmonary dysplasia (BPD) will be performed at protocol defined timeframes. Neonates enrolled in the study will have fecal/meconium samples collected daily through 4 days following the start of dosing and weekly thereafter until NICU discharge to determine fecal shedding of STP6 and STP11. Following completion of blinded study treatment dosing, neonates will be evaluated at 1 week, 4 weeks, 3 months, and 6 months for safety and growth assessments.

Neonates will be stratified into the following four birth weights: 2000-1501g, 1500 to 1000 g, 999 to 750 g and 749 to 500 g. Each birth weight stratum will contain 2 dosing groups - a low dose STP206 group and a high dose STP206 group. Within each birth weight strata/dose level, subjects will be randomized in a 2:1 ratio to the STP206 or control group. Enrollment of neonates into study groups will occur sequentially. Enrollment into the high dose group within a birth weight stratum will not proceed until after the safety data from the low dose group is reviewed by the study independent Data Safety Monitoring Committee (DSMC). Similarly, enrollment into the next lower birth weight stratum will not proceed until the safety data from the high dose group of the prior weight stratum is reviewed by the study independent Data Safety Monitoring Committee (DSMC).

Eligibility criteria: Inclusion Criteria:

1. Neonates with birth weights between 2000-500g for Part A and 1500-500g for Part B
2. Ability to start treatment within four days after birth.
3. Gestational age between 23 and 32 weeks at birth
4. Obtaining of informed consent from the subject's mother after full understanding of the study purpose and procedures.
5. Parents who agree to allow the Principal Investigator and his/her staff to follow the procedures and assessments required by the protocol

Exclusion Criteria:

1. Infants with, or at high probability for, early onset sepsis (positive blood cultures or with clinical/histological chorioamnionitis with the expectation of empirical antimicrobial therapy for ≥5 days)
2. Infants with persistent pulmonary hypertension of the newborn (PPHN)
3. Congenital or chromosomal anomalies
4. Congenital or acquired gastrointestinal pathology that preclude feeds soon after birth (e.g. cleft lip is not an exclusion criterion, but a duodenal atresia is)
5. Infants in extremis to whom no further intensive care is offered by attending neonatologist (e.g., infant being provided only hospice/comfort care)
6. Other conditions of the infant which, in the opinion of the attending neonatologist, preclude participation
7. Positive maternal HIV status
8. Participation in another interventional clinical trial

   For Part A of the study, the following additional exclusion criterion will apply:
9. Small for gestational age neonates, i.e. neonates that weigh less that the 10th percentile for their gestational age according to the Estimated Fetal Weight Percentile Chart

Primary outcomes:
measure: Number and Severity of Adverse Events Experienced by Subjects in Low-dose Treatment Groups
timeFrame: 30 days after the last dose of blinded study treatment
measure: Number and Severity of Adverse Events Experienced by Subjects in High-Dose Treatment Groups
timeFrame: 30 days after the last dose of blinded study treatment
measure: Treatment-emergent Adverse Events Experienced by Subjects in Low-Dose Treatment Groups
timeFrame: 30 days after last administration of study drug
measure: Treatment-emergent Adverse Events Experienced by Subjects in High-Dose Treatment Groups
timeFrame: 30 days after last administration of study drug
measure: Grade 3 Treatment-emergent Adverse Events Experienced by Subjects in Low-Dose Treatment Groups
timeFrame: 30 days after last administration of study drug
measure: Grade 3 Treatment-emergent Adverse Events Experienced by Subjects in High-Dose Treatment Groups
timeFrame: 30 days after last administration of study drug
measure: Serious Adverse Events Experienced by Subjects in Low-Dose Treatment Groups
timeFrame: 30 days after last administration of study drug
measure: Serious Adverse Events Experienced by Subjects in High-Dose Treatment Groups
timeFrame: 30 days after last administration of study drug
measure: Growth Assessment Classification in Low-Dose Treatment Groups
timeFrame: End of dosing/hospital discharge, up to 781 days
measure: Growth Assessment Classification in High-Dose Treatment Groups
timeFrame: End of dosing/hospital discharge, up to 781 days
Secondary outcomes:
measure: Number of Patients With Suspected Necrotizing Enterocolitis in Low-Dose Treatment Groups
timeFrame: Start of dosing to 6 months
measure: Number of Patients With Suspected Necrotizing Enterocolitis in High-Dose Treatment Groups
timeFrame: Start of dosing to 6 months
measure: Number of Patients With Confirmed Necrotizing Enterocolitis in Low-Dose Treatment Groups
timeFrame: Start of dosing to 6 months
measure: Number of Patients With Confirmed Necrotizing Enterocolitis in High-Dose Treatment Groups
timeFrame: Start of dosing to 6 months
measure: Number of Patients With Sepsis in Low-Dose Treatment Groups
timeFrame: Start of dosing to 6 months
measure: Number of Patients With Sepsis in High-Dose Treatment Groups
timeFrame: Start of dosing to 6 months
measure: Number of Patients With Feeding Intolerance in Low-Dose Treatment Groups
timeFrame: Start of dosing to 6 months
measure: Number of Patients With Feeding Intolerance in High-Dose Treatment Groups
timeFrame: Start of dosing to 6 months
measure: Number of Patients With Retinopathy of Prematurity in Low-Dose Treatment Groups
timeFrame: Start of dosing to 6 months
measure: Number of Patients With Retinopathy of Prematurity in High-Dose Treatment Groups
timeFrame: Start of dosing to 6 months
measure: Number of Patients With Intraventricular Hemorrhage in Low-Dose Treatment Groups
timeFrame: From 5 days to 28 days
measure: Number of Patients With Intraventricular Hemorrhage in High-Dose Treatment Groups
timeFrame: From 5 days to 28 days
measure: Number of Patients With Bronchopulmonary Dysplasia in Low-Dose Treatment Groups
timeFrame: Start of dosing to 6 months
measure: Number of Patients With Bronchopulmonary Dysplasia in High-Dose Treatment Groups
timeFrame: Start of dosing to 6 months
measure: Number of Patients With Fecal Shedding of STP6 and STP11 in Low-Dose Treatment Groups
timeFrame: Prior to Week 1 Day 4 and at end of dosing/hospital discharge, up to 781 days
measure: Number of Patients With Fecal Shedding of STP6 and STP11 in High-Dose Treatment Groups
timeFrame: Prior to Week 1 Day 4 and at end of dosing/hospital discharge, up to 781 days
Other outcomes:
Locations:
city: Hartford
country: United States
facility: Connecticut Children's Medical Center
state: Connecticut
city: Sunrise
country: United States
facility: Sheridan Clinical Research / Plantation General Hospital
state: Florida
city: Augusta
country: United States
facility: Augusta University
state: Georgia
city: Evanston
country: United States
facility: NorthShore University HealthSystem
state: Illinois
city: Springfield
country: United States
facility: Southern Illinois University School of Medicine
state: Illinois
city: Wichita
country: United States
facility: Wesley Medical Center
state: Kansas
city: Boston
country: United States
facility: Beth Israel Deaconess Medical Center
state: Massachusetts
city: Springfield
country: United States
facility: Baystate Medical Center
state: Massachusetts
city: Raleigh
country: United States
facility: WakeMed Health and Hospitals
state: North Carolina
city: Charleston
country: United States
facility: Medical University South Carolina
state: South Carolina
city: Memphis
country: United States
facility: University of Tennessee
state: Tennessee
city: Plano
country: United States
facility: The Medical Center of Plano
state: Texas
city: Morgantown
country: United States
facility: West Virginia University
state: West Virginia
Study officials:
affiliation: Endeavor Health
name: Michael S Caplan, MD
role: PRINCIPAL_INVESTIGATOR
References: